Neuphoria Therapeutics vs Ovid Therapeutics
NEUP and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NEUP and OVID compare
Ovid Therapeutics scores higher on the StockData Score (9 against 5 for Neuphoria Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NEUP | OVID |
|---|---|---|
| Size and price | ||
| Market cap | – | $496M |
| Share price | $2.55 | $2.54 |
| Change, 1 year | −48.0% | 92.4% |
| Change, 5 years | – | −26.2% |
| Beta (5Y) | 0.86 | 1.22 |
| Employees | 7 | 23 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 342× |
| P/B | – | 2.5× |
| Growth | ||
| Revenue growth (TTM) | – | −78.0% |
| Revenue growth, 5Y average | – | −10.5% |
| Profitability | ||
| Operating margin | – | −4700% |
| Net margin | – | −2971% |
| Return on equity | −61.7% | −35.4% (better) |
| Return on invested capital | −273% | −191% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 27.85 (better) | 11.97 |
| Altman Z-score | – | 9.96 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 36.8% | 75.3% |
| Held by insiders | – | 13.6% |
| Insider net buying, 12 months | $0 (better) | −$29.3K |
| Short interest, % of float | – | 10.8% |
Go deeper
- NEUP stock overview
- NEUP income statement
- NEUP valuation and score
- OVID stock overview
- OVID income statement
- OVID valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.